Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Tuesday, April 29th, 2025

Beverly JCG Ltd. Announces Subscription of 11.9 Million New Shares at S$0.0084 to Strengthen Capital Base

Discounted Share Subscription Shake-Up: Beverly JCG Ltd’s Strategic Capital Injection Set to Impact Share Price

Discounted Share Subscription Shake-Up: Beverly JCG Ltd’s Strategic Capital Injection Set to Impact Share Price

Beverly JCG Ltd has announced a notable capital-raising move that could have price-sensitive implications for shareholders. The company has entered into a subscription agreement with private investor Leow Hoi Loong to issue 11,904,761 new ordinary shares at an issue price of S\$0.0084 per share, amounting to gross proceeds of S\$100,000.

Key Details of the Subscription

  • Subscription Agreement: Dated 3 March 2025, the agreement outlines the issuance of 11,904,761 shares through a private placement exemption under Section 272B of the Securities and Futures Act.
  • Discounted Issue Price: The shares are being offered at S\$0.0084, representing a 9.68% discount to the volume weighted average price (VWAP) of S\$0.0093 observed on the SGX-ST trading day.
  • Capital Usage: The net proceeds — approximately S\$100,000 — are slated primarily for working capital (90%) with a minor allocation (10%) toward funding growth, development, and expansion in the company’s core medical aesthetics and healthcare business, as well as exploring new business opportunities.
  • Allotment Mechanism: The share issuance is carried out pursuant to the Share Issue Mandate passed by shareholders at the AGM on 29 April 2024. The additional shares fall well within the limits of the approved mandate.
  • Investor Profile: Leow Hoi Loong, identified by the Deputy Chairman and CEO, is a private investor with no prior direct or indirect relationship with the company, thereby ensuring this is an arm’s-length transaction.
  • Conditions and Approvals: Completion of the subscription is subject to standard conditions, including confirmation of the Share Issue Mandate’s validity, in-principle approval for listing the new shares on the Catalist board by the SGX-ST (subject to acceptable conditions), compliance with regulatory requirements, and satisfactory outcomes from Know-Your-Client (KYC) and due diligence checks.

Potentially Price-Sensitive Information for Shareholders

  • Discounted Entry Point: The sale at a price below the average trading price may signal positive pricing dynamics, potentially impacting share liquidity and investor sentiment.
  • Strategic Use of Proceeds: The proceeds will bolster the company’s working capital, which could lead to enhanced operational flexibility and growth. The allocation towards immediate working capital (90%) underlines the firm’s focus on maintaining robust cash flows amid ongoing expansions.
  • Non-Dilutive Limits and Future Issuances: Given the share issuance is executed under a pre-approved mandate, shareholders can be confident that further dilutive measures are controlled, though the cumulative effects (including past and potential future issuances) remain an important consideration.
  • Listing on Catalist: A subsequent application for listing the new subscription shares on the Catalist board suggests further visibility, and any fluctuations in approval matters could trigger significant market reactions.

Financial Implications

The company has illustrated the financial effects as an exercise in showcasing its commitment to strengthening its balance sheet:

  • Net Tangible Assets (NTA): Post-subscription, the NTA per share is expected to improve marginally from 0.252 cents to 0.236 cents (based on FY2023 data). Although the absolute numbers appear modest, the improved capital base may support future operational investments.
  • Loss Per Share (LPS): A slight compression in the LPS from 0.355 cents to 0.349 cents is demonstrated on a fully diluted basis, thus contributing to the overall narrative of financial stabilization.

Broader Strategic Implications

Beyond the immediate capital raise, this subscription signals a broader strategic initiative by Beverly JCG Ltd to reinforce its financial standing amid expansion plans. The emphasis on dedicated working capital ensures that the company is well-positioned to navigate both operational challenges and opportunities in the evolving landscape of medical aesthetics and healthcare.

Additionally, the board’s confirmation that the company currently possesses adequate working capital, independent of the subscription, adds a layer of reassurance. However, the infusion from the subscription provides an extra cushion and demonstrates proactive capital management.

Conclusion

The privately placed discounted share subscription is a tactical move by Beverly JCG Ltd that carries several potential price-sensitive indicators. Shareholders and market participants should monitor the developments surrounding the Catalist listing application and the eventual impact on working capital that could influence both operational expansion and investor sentiment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research or consult professional advisors before making any investment decisions.


View BeverlyJCG Historical chart here



Voluntary Unconditional Cash Offer for Sin Heng Heavy Machinery Limited

Potential Delisting of Sin Heng Heavy Machinery Limited: Investors Brace for Significant Changes Key Highlights: TAL United Pte. Ltd. (the “Offeror”) has made a voluntary unconditional cash offer to acquire all the issued and...

Major Bank’s Subsidiary Enters Complex Derivatives Deal Amid Suntec REIT Takeover Bid

Suntec REIT: OCBC’s Strategic Move Could Influence Share Prices Suntec REIT: OCBC’s Strategic Move Could Influence Share Prices OCBC Bank has made a significant disclosure regarding its dealings in Suntec Real Estate Investment Trust...

Micro-Mechanics Announces Dividend Payment Date and Record Date for FY2025 Interim Dividend

Micro-Mechanics Declares Interim Dividend and Record Date for FY2025 Micro-Mechanics Declares Interim Dividend and Record Date for FY2025 Micro-Mechanics (Holdings) Ltd. (the “Company”) has officially announced the declaration of an interim one-tier tax-exempt dividend...